Morning all ..28 Feb 2021 08:44
Interesting debate .. scancell is a different animal now since I started following the story in 2012 ... they ran the phase 1/2 scib1 trial when they had fewer staff and cash ... Covidity will run in my opinion ..
Also agree that there is much more going on than Covidity although that is the hot topic currently for instance Avidimab and as it says in the presentation it’s multiple licensing opportunities ...
I also agree that Cliffs delivery technique is a little dry but I’m not invested in his personality I’m invested in scancells protected science.
Scancell has moved and developed since I started following , it certainly is not a ‘stagnant’ aim company ... it’s value is currently determined by institutional investment and aim traders ... there has yet to be a pharmaceutical industry valuation of any of its science .. that’s what I’m waiting for ... question is ... how long will that wait be ?? Nobody knows ... enjoy the ride til then .. or just sit on the rollercoaster and relax ..
With all those brains on board now too I can’t see the track running out any time soon !
Take care all !